A clash of quality systems looms at the as-yet unnamed venture announced 29 July that combines generics giant Mylan NV with Pfizer Inc.’s [Upjohn Laboratories] unit to treat non-communicable diseases of affluence spreading in emerging economies.
The venture will face the challenge of combining two quality systems, one rooted in generic drugs for developed markets and...